Topiroxostat controlled-release tablet and preparation method thereof

Abstract

The invention discloses a topiroxostat controlled-release tablet and a preparation method thereof. The topiroxostat controlled-release tablet is composed of a drug-containing tablet core and a coating membrane layer covering the drug-containing tablet core, the drug-containing tablet core comprises topiroxostat, a filling agent and sodium chloride, and the coating membrane layer comprises a controlled-release material, plasticizer and a pore-foaming agent. During preparation, the drug-containing tablet core is wrapped with the coating membrane layer, and the topiroxostat controlled-release tablet is obtained. The topiroxostat controlled-release tablet and the preparation method thereof are characterized in that the topiroxostat controlled-release tablet is composed of a quick-release part and a controlled-release part; after the topiroxostat controlled-release tablet enters a human body, the quick-release part is released rapidly, a certain plasma concentration is achieved, the controlled-release part is released slowly, the certain plasma concentration is maintained, good drug efficacy can be achieved, and the side effect of the drug can be effectively avoided. The topiroxostat controlled-release tablet has the advantages of being rapid to dissolve, rapid to absorb, high in bioavailability, good in stability, convenient to take and the like, and therefore the side effect brought by taking the drug to a patient is reduced. The preparation technology is simple, the obtained product is stable in quality, and the preparation method is suitable for large-scale production.

Description

technical field [0001] The invention relates to the technical field of chemical drug controlled-release tablets, in particular to a topicastat controlled-release tablet, and also relates to a preparation method of the controlled-release tablet. Background technique [0002] Uric acid is a normal product of purine nucleotide metabolism. When uric acid is produced excessively and uric acid excretion decreases, hyperuricemia is formed when the uric acid in the blood rises beyond the normal range; excessive uric acid in the blood is mainly deposited in the joints, cartilage, Subcutaneous soft tissue and kidneys cause comprehensive clinical manifestations such as arthritis and kidney disease, which is called gout. Therefore, hyperuricemia and uric acid deposition in organ tissues are the basic pathogenesis of gout. The etiology leading to elevated uric acid is more complex and can be divided into two categories: primary and secondary. [0003] With the improvement of people's li...

AI Technical Summary

Problems solved by technology

[0004] At present, the number of gout patients in my country is still increasing, and there is a trend of spreading to a younger age. Therefore, anti-gout drugs have great potential in the Chinese market. However, most of the anti-gout drugs on the market are old drugs. Although they are cheap, they have obvious side effects. , if there are new drugs launched in time, the market prospect will be very impressive

Images